Changes in Mirna Expression in a Model of Microcephaly Shan Parikh University of Connecticut - Storrs, [email protected]
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Anti-EIF2C1 / AGO1 Antibody (ARG63916)
Product datasheet [email protected] ARG63916 Package: 100 μg anti-EIF2C1 / AGO1 antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes EIF2C1 / AGO1 Tested Reactivity Hu Predict Reactivity Ms, Rat, Dog Tested Application IHC-P, WB Specificity This product is not expected to cross-react with EIF2C2, EIF2C3 and EIF2C4. Host Goat Clonality Polyclonal Isotype IgG Target Name EIF2C1 / AGO1 Antigen Species Human Immunogen C-KNASYNLDPYIQEF Conjugation Un-conjugated Alternate Names GERP95; Q99; eIF2C 1; EIF2C; EIF2C1; Argonaute RISC catalytic component 1; Argonaute1; Protein argonaute-1; hAgo1; Putative RNA-binding protein Q99; eIF-2C 1; Eukaryotic translation initiation factor 2C 1 Application Instructions Application table Application Dilution IHC-P 2.5 µg/ml WB 0.3 - 1 µg/ml Application Note WB: Recommend incubate at RT for 1h. IHC-P: Antigen Retrieval: Steam tissue section in Citrate buffer (pH 6.0). * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 97 kDa Properties Form Liquid Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA Preservative 0.02% Sodium azide Stabilizer 0.5% BSA www.arigobio.com 1/3 Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. -
Gene Expression During Normal and FSHD Myogenesis Tsumagari Et Al
Gene expression during normal and FSHD myogenesis Tsumagari et al. Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 (27 September 2011) Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 RESEARCHARTICLE Open Access Gene expression during normal and FSHD myogenesis Koji Tsumagari1, Shao-Chi Chang1, Michelle Lacey2,3, Carl Baribault2,3, Sridar V Chittur4, Janet Sowden5, Rabi Tawil5, Gregory E Crawford6 and Melanie Ehrlich1,3* Abstract Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Methods: Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Results: Many of the ~17,000 examined genes were differentially expressed (> 2-fold, p < 0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis- specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. -
Small Rnas in Early Mammalian Development: from Gametes to Gastrulation Nayoung Suh and Robert Blelloch*
REVIEW 1653 Development 138, 1653-1661 (2011) doi:10.1242/dev.056234 © 2011. Published by The Company of Biologists Ltd Small RNAs in early mammalian development: from gametes to gastrulation Nayoung Suh and Robert Blelloch* Summary Classes and biogenesis of mammalian small RNAs Small non-coding RNAs, including microRNAs (miRNAs), Three major classes of functional small non-coding RNAs have endogenous small interfering RNAs (endo-siRNAs) and Piwi- been found in mammals: microRNAs (miRNAs), endogenous interacting RNAs (piRNAs), play essential roles in mammalian small interfering RNAs (endo-siRNAs) and Piwi-interacting RNAs development. The function and timing of expression of these (piRNAs) (Babiarz and Blelloch, 2009; Kim et al., 2009; Thomson three classes of small RNAs differ greatly. piRNAs are expressed and Lin, 2009). These classes differ in their biogenesis, i.e. their and play a crucial role during male gametogenesis, whereas maturation from transcribed forms to the active form of the RNA endo-siRNAs are essential for oocyte meiosis. By contrast, (Fig. 1). miRNAs are ubiquitously expressed in somatic tissues and miRNAs can be divided into two subclasses: canonical and non- function throughout post-implantation development. canonical miRNAs. Canonical miRNAs are initially transcribed as Surprisingly, however, miRNAs are non-essential during pre- long RNAs that contain hairpins (Fig. 1A). The 60-75 nt hairpins implantation embryonic development and their function is are recognized by the RNA-binding protein Dgcr8 (DiGeorge suppressed during oocyte meiosis. Here, we review the roles of syndrome critical region 8), which directs the RNase III enzyme small non-coding RNAs during the early stages of mammalian Drosha to cleave the base of the hairpin (Denli et al., 2004; development, from gamete maturation through to Gregory et al., 2004; Han et al., 2004; Han et al., 2006; Landthaler gastrulation. -
Application to Neuroimaging Biomarkers in Alzheimer's
The Author(s) BMC Medical Informatics and Decision Making 2017, 17(Suppl 1):61 DOI 10.1186/s12911-017-0454-0 RESEARCH Open Access Knowledge-driven binning approach for rare variant association analysis: application to neuroimaging biomarkers in Alzheimer’s disease Dokyoon Kim1,2, Anna O. Basile2, Lisa Bang1, Emrin Horgusluoglu4, Seunggeun Lee3, Marylyn D. Ritchie1,2, Andrew J. Saykin4 and Kwangsik Nho4* From The 6th Translational Bioinformatics Conference Je Ju Island, Korea. 15-17 October 2016 Abstract Background: Rapid advancement of next generation sequencing technologies such as whole genome sequencing (WGS) has facilitated the search for genetic factors that influence disease risk in the field of human genetics. To identify rare variants associated with human diseases or traits, an efficient genome-wide binning approach is needed. In this study we developed a novel biological knowledge-based binning approach for rare-variant association analysis and then applied the approach to structural neuroimaging endophenotypes related to late-onset Alzheimer’sdisease(LOAD). Methods: For rare-variant analysis, we used the knowledge-driven binning approach implemented in Bin-KAT, an automated tool, that provides 1) binning/collapsing methods for multi-level variant aggregation with a flexible, biologically informed binning strategy and 2) an option of performing unified collapsing and statistical rare variant analyses in one tool. A total of 750 non-Hispanic Caucasian participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort who had both WGS data and magnetic resonance imaging (MRI) scans were used in this study. Mean bilateral cortical thickness of the entorhinal cortex extracted from MRI scans was used as an AD-related neuroimaging endophenotype. -
Gene Ontology Functional Annotations and Pleiotropy
Network based analysis of genetic disease associations Sarah Gilman Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2013 Sarah Gilman All Rights Reserved ABSTRACT Network based analysis of genetic disease associations Sarah Gilman Despite extensive efforts and many promising early findings, genome-wide association studies have explained only a small fraction of the genetic factors contributing to common human diseases. There are many theories about where this “missing heritability” might lie, but increasingly the prevailing view is that common variants, the target of GWAS, are not solely responsible for susceptibility to common diseases and a substantial portion of human disease risk will be found among rare variants. Relatively new, such variants have not been subject to purifying selection, and therefore may be particularly pertinent for neuropsychiatric disorders and other diseases with greatly reduced fecundity. Recently, several researchers have made great progress towards uncovering the genetics behind autism and schizophrenia. By sequencing families, they have found hundreds of de novo variants occurring only in affected individuals, both large structural copy number variants and single nucleotide variants. Despite studying large cohorts there has been little recurrence among the genes implicated suggesting that many hundreds of genes may underlie these complex phenotypes. The question -
WO 2012/170711 Al 13 December 2012 (13.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/170711 Al 13 December 2012 (13.12.2012) P O P C T (51) International Patent Classification: (72) Inventors; and G01N33/5 74 (2006.01) (75) Inventors/Applicants (for US only): PAWLOWSKI, Traci [US/US]; 2014 N Milkweed Loop, Phoenix, AZ (21) International Application Number: 85037 (US). YEATTS, Kimberly [US/US]; 109 E. Pierce PCT/US2012/041387 Street, Tempe, AZ 85281 (US). AKHAVAN, Ray (22) International Filing Date: [US/US]; 5804 Malvern Hill Ct, Haymarket, VA 201 69 7 June 2012 (07.06.2012) (US). (25) Filing Language: English (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N. MacArthur Blvd., Irving, TX 75039 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 61/494,196 7 June 201 1 (07.06.201 1) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 61/494,355 7 June 201 1 (07.06.201 1) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 61/507,989 14 July 201 1 (14.07.201 1) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant (for all designated States except US): CARIS HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LIFE SCIENCES LUXEMBOURG HOLDINGS, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, S.A.R.L [LU/LU]; Rue De Maraichers, L2124 Luxem MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, bourg, Grand-Duche De Luxembourg (LU). -
WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
The Argonaute Family: Tentacles That Reach Into Rnai, Developmental Control, Stem Cell Maintenance, and Tumorigenesis
Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis Michelle A. Carmell,1,2,3 Zhenyu Xuan,1,3 Michael Q. Zhang,1 and Gregory J. Hannon1,4 1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; 2Program in Genetics, State University of New York at Stony Brook, Stony Brook, New York 11794, USA RNA interference (RNAi) is an evolutionarily conserved The Argonaute family process through which double-stranded RNA (dsRNA) Argonaute proteins make up a highly conserved family induces the silencing of cognate genes (for review, see whose members have been implicated in RNAi and re- Bernstein et al. 2001b; Carthew 2001). Sources of dsRNA lated phenomena in several organisms. In addition to silencing triggers include experimentally introduced roles in RNAi-like mechanisms, Argonaute proteins in- dsRNAs, RNA viruses, transposons, and RNAs tran- fluence development, and at least a subset are involved scribed from complex transgene arrays (for review, see in stem cell fate determination. Argonaute proteins are Hammond et al. 2001b). Short hairpin sequences en- ∼100-kD highly basic proteins that contain two common coded in the genome also appear to enter the RNAi path- domains, namely PAZ and PIWI domains (Cerutti et al. way and function to regulate the expression of endog- 2000). The PAZ domain, consisting of 130 amino acids, enous, protein-coding genes (Grishok et al. 2001; has been identified in Argonaute proteins and in Dicer Hutvagner et al. 2001; Ketting et al. -
(12) Patent Application Publication (10) Pub. No.: US 2009/0113561 A1 Von Melchner Et Al
US 2009.0113561A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0113561 A1 Von Melchner et al. (43) Pub. Date: Apr. 30, 2009 (54) GENE TRAP CASSETTES FOR RANDOM (30) Foreign Application Priority Data AND TARGETED CONDITIONAL GENE NACTIVATION Nov. 26, 2004 (EP) .................................. O4O281941 Apr. 18, 2005 (EP) .................................. O5103092.2 (75) Inventors: Harald Von Melchner, Publication Classification Kronberg/Taunus (DE); Frank (51) Int. Cl Schnutgen, Alzenau (DE); AOIK 67/027 (2006.01) Particia Ruiz, Berlin (DE): Silke CI2N 15/87 (2006.01) De-Zolt, Rodenbach (DE); Thomas CI2O I/68 (2006.01) Floss, Oberappersdorf (DE); Jens CI2N 5/06 (2006.01) Hansen, Kirchheim (DE) (52) U.S. Cl. .............. 800/3:536/23.1; 435/325; 800/13; 435/455: 800/25; 435/6:435/463 Correspondence Address: (57) ABSTRACT NORRIS, MCLAUGHILIN & MARCUS, PA 875 THIRDAVENUE, 18TH FLOOR A new type of gene trap cassette, which can induce condi NEW YORK, NY 10022 (US) tional mutations, relies on directional site-specific recombi nation systems, which can repair and re-induce gene trap (73) Assignee: FRANKGEN mutations when activated in Succession. After the gene trap cassettes are inserted into the genome of the target organism, BIOTECHNOLOGIE AG, mutations can be activated at a particular time and place in Kronberg (DE) Somatic cells. The gene trap cassettes also create multipur pose alleles amendable to a wide range of post-insertional (21) Appl. No.: 11/720,231 modifications. Such gene trap cassettes can be used to muta tionally inactivate all cellular genes temporally and/or spa (22) PCT Filed: Nov. -
A SARS-Cov-2 Protein Interaction Map Reveals Targets for Drug Repurposing
Article A SARS-CoV-2 protein interaction map reveals targets for drug repurposing https://doi.org/10.1038/s41586-020-2286-9 A list of authors and affiliations appears at the end of the paper Received: 23 March 2020 Accepted: 22 April 2020 A newly described coronavirus named severe acute respiratory syndrome Published online: 30 April 2020 coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than Check for updates 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efcacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and eforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identifed the human proteins that physically associated with each of the SARS-CoV-2 proteins using afnity-purifcation mass spectrometry, identifying 332 high-confdence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. -
SPEF2 Functions in Microtubule-Mediated Transport in Elongating Spermatids to Ensure Proper Male Germ Cell Differentiation Mari S
© 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 2683-2693 doi:10.1242/dev.152108 RESEARCH ARTICLE SPEF2 functions in microtubule-mediated transport in elongating spermatids to ensure proper male germ cell differentiation Mari S. Lehti1,2,*, Fu-Ping Zhang2,3,*, Noora Kotaja2,* and Anu Sironen1,‡,§ ABSTRACT 2006, 2002). Mutations in the Spef2 gene (an amino acid substitution Sperm differentiation requires specific protein transport for correct within exon 3 and a nonsense mutation within exon 28) in the big giant sperm tail formation and head shaping. A transient microtubular head (bgh) mouse model caused a primary ciliary dyskinesia (PCD)- structure, the manchette, appears around the differentiating like phenotype, including hydrocephalus, sinusitis and male infertility spermatid head and serves as a platform for protein transport to the (Sironen et al., 2011). Detailed analysis of spermatogenesis in both pig growing tail. Sperm flagellar 2 (SPEF2) is known to be essential for and mouse models revealed axonemal abnormalities, including defects sperm tail development. In this study we investigated the function of in central pair (CP) structure and the complete disorganization of the SPEF2 during spermatogenesis using a male germ cell-specific sperm tail (Sironen et al., 2011). A role of SPEF2 in protein transport Spef2 knockout mouse model. In addition to defects in sperm tail has been postulated owing to its known interaction and colocalization development, we observed a duplication of the basal body and failure with intraflagellar transport 20 (IFT20). During spermatogenesis, in manchette migration resulting in an abnormal head shape. We IFT20 and SPEF2 colocalize in the Golgi complex of late identified cytoplasmic dynein 1 and GOLGA3 as novel interaction spermatocytes and round spermatids and in the manchette and basal partners for SPEF2. -
Initial Whole-Genome Sequencing and Analysis of the Host Genetic
Wang et al. Cell Discovery (2020) 6:83 Cell Discovery https://doi.org/10.1038/s41421-020-00231-4 www.nature.com/celldisc ARTICLE Open Access Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility Fang Wang1, Shujia Huang2,3, Rongsui Gao1, Yuwen Zhou2,4, Changxiang Lai1,ZhichaoLi2,4, Wenjie Xian1, Xiaobo Qian2,4,ZhiyuLi1, Yushan Huang2,4,QiyuanTang1, Panhong Liu2,4, Ruikun Chen1, Rong Liu2,XuanLi1, Xin Tong 2, Xuan Zhou1, Yong Bai 2,GangDuan1, Tao Zhang 2,XunXu 2,5,JianWang2,6,HuanmingYang2,6, Siyang Liu2,QingHe1,XinJin2,3 and Lei Liu1 Abstract The COVID-19 pandemic has accounted for millions of infections and hundreds of thousand deaths worldwide in a short-time period. The patients demonstrate a great diversity in clinical and laboratory manifestations and disease severity. Nonetheless, little is known about the host genetic contribution to the observed interindividual phenotypic variability. Here, we report the first host genetic study in the Chinese population by deeply sequencing and analyzing 332 COVID-19 patients categorized by varying levels of severity from the Shenzhen Third People’s Hospital. Upon a total of 22.2 million genetic variants, we conducted both single-variant and gene-based association tests among five severity groups including asymptomatic, mild, moderate, severe, and critical ill patients after the correction of potential confounding factors. Pedigree analysis suggested a potential monogenic effect of loss of function variants in GOLGA3 and DPP7 for critically ill and asymptomatic disease demonstration. Genome-wide association study suggests the most 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; significant gene locus associated with severity were located in TMEM189–UBE2V1 that involved in the IL-1 signaling pathway.